Lilly and Daiichi Sankyo try to quash prasugrel panel meeting rumours
This article was originally published in Scrip
Lillyand Daiichi Sankyoare attempting to damp down rumours over the progress of the US NDA for their novel antiplatelet agent prasugrel (Effient). In a joint statement, the companies, which are co-developing the potential blockbuster, say that they have not been notified of any regulatory action for the NDA or of any decision to have an advisory panel to review the drug. Speculation has mounted that the FDAwas contemplating taking the drug to a panel review, following its failure to complete a review of the product by the PDUFA user fee deadline of September 26th.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.